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Protease-activated receptors (PARs) have been implicated in a variety of human 
physiological and pathophysiological processes, including; nociception, 
neuroinflammation, neuroprotective and neurodegenerative pathways (Peters and 
Henry, 2009; Adams et al. 2011).  PAR3 was discovered as a second thrombin 
receptor in 1997, and since then few papers have been published which assess its 
expression in the nervous system (Ishihara et al. 1997).  This paper investigates the 
expression of PAR3 in sensory neurons of the trigeminal ganglion (TG) and dorsal 
root ganglion (DRG) of naïve adult rats.  Immunohistochemistry showed PAR3 to be 
strongly expressed in non-neuronal cells of both the TG and DRG.  Further analysis 
showed these cells to be non-myelinating satellite cells and myelinating Schwann 
cells, both showing strong co-expression of PAR3 and S-100.  The expression of 
PAR3 in sensory neurons proved too difficult to accurately determine.  This study 
concludes that further research, using multiple methods of analysis, is required to 
accurately describe the distribution and quantification of PAR3 positive sensory 
neurons within the TG and DRG of naïve adult rats.  This study does however show 
strong PAR3 expression in non-neuronal satellite cells and Schwann cells of both the 












Protease-activated receptors (PARs) are a family of four seven-transmembrane G 
protein-coupled receptors (GPCR), activated by protease cleavage (Ramachandran 
et al. 2012).  PAR1, PAR3 and PAR4 are preferentially activated by thrombin, 
whereas PAR2 is primarily activated by trypsin (García et al. 2010).  Cleavage of the 
extracellular N-terminal domain results in the exposure of a tethered peptide ligand, 
which binds and activates the receptor (Vellani et al. 2010).  This novel mechanism 
of activation is in contrast with other GPCRs; which, unlike PARs, can be activated 
by soluble ligand binding in vivo (Adams, 2011).  PARs have been implicated in a 
variety of human physiological as well as pathophysiological processes (Peters and 
Henry, 2009), with in vitro and in vivo experimental evidence linking PARs to 
processes involved in the nervous system; including nociception, neuroinflammation, 
neuroprotective and neurodegenerative pathways (Adams et al. 2011).  Even though 
strong experimental evidence link PARs with functional processes in the nervous 
system, their precise expression in sensory neurons is still relatively unknown.  This 
gap in knowledge is particularly evident when reviewing literature relating to the 
expression of PAR3 in the sensory neurones of the TG, with relatively few studies 
confirming its expression in the DRG. 
 
In 1998, Gill and colleagues first reported a functional response to thrombin in 
sensory neurons of the dorsal root ganglion (DRG) in rat models, where thrombin 
was shown to reverse stellation in neuroblastoma cell lines and rat astrocytes, 
respectively, and induce neurite retraction.  However it wasn’t until 2005 when Zhu 
and colleagues showed mRNA for all four PAR subtypes are expressed in sensory 
neurons of the DRG, using rat models.  In particular, PAR3 mRNA was shown to be 
expressed in 40.9± 1.3% of the total neuron population of the DRG, based on scatter 
plot analysis of hybridisation signals (Zhu et al. 2005).  Zhu et al. (2005), using size-
frequency analysis demonstrated PAR3 mRNA was expressed across all neuron 
sizes in the DRG with no preferential expression.  This was the first study, in adult rat 
DRG, to report the precise expression of PAR-3 mRNA by in situ hybridisation.  Their 
work found high co-localisation between CGRP and PAR3 mRNA, suggesting a role 
for PAR3 in nociceptive mechanisms in the periphery.  Many studies in platelets 
have shown PAR3 acts as a cofactor for PAR4 following activation by thrombin 
(Nakanishi-Matsui et al. 2000).  Interestingly however, Zhu and colleagues (2005) 
found no PAR4 expressing neurons in the DRG, with PAR4 expression shown to be 
in non-neuronal cells such as satellite cells.  The author suggests that the activation 
of PAR3 in the nervous system may be different from that in platelets, with PAR3 
acting independently of PAR4. 
 
More recent work by Vellani and colleagues (2010) used experimental techniques, 
such as in situ hybridisation and immunohistochemistry, to quantify PAR expression 
in sensory neurones of the DRG of adult mice.  Although this study was conducted 
using a different species, Vellani et al. (2010) found few qualitative or quantitative 
differences between PAR expression in rat and mice DRG.  PAR3 was shown to be 
strongly expressed in 42% of neurones, using immunohistochemistry, predominantly 
in small neurons (Vellani et al. 2010).  However a significant reduction in the 
proportions of neurones expressing PAR3 was found when the authors used 
functional expression analysis, compared with the histological data.  Experimentally 
induced desensitisation of PAR1 and PAR4 largely ablated neuronal response to 
thrombin suggesting PAR3 is either not functional in sensory neurones or that it can 





only act in combination with other PARs, a hypothesis which has been noted in other 
studies (Nakanishi-Matsui et al. 2000; McLaughlin et al. 2007; Vellani et al. 2010).  
The authors suggest this was the first study to assess the localisation of functional 
thrombin activated PARs in sensory neurons of the DRG. 
 
The expression of PAR2 in trigeminal neurons (Dinh et al. 2005) has been assessed 
however, to the best of my knowledge there are no studies assessing the expression 
of PAR3 in sensory neurones of the TG.   
 
The aim of this study is to describe the distribution and quantification of PAR3 in 
sensory neurons of the TG and DRG of naïve adult rats (as a model for human 
expression) using immunohistochemistry.  Expression of PAR3 was also 




Method and Materials 
Animal/Tissue Preparation 
Experiments were carried out on two adult naïve male Wistar rats, with a body 
weight range between 220-250g (Charles River, Margate, UK).  All procedures were 
conducted in accordance with the UK 1986 Animals (Scientific Procedures) Act.  The 
animals were on a 12:12 hour light/dark cycle, housed in a temperature controlled 
room.  Food and water was available ad libitum.  Following Schedule 1 killing, the 
animals were transcardially perfused with 0.01 M phosphate-buffered saline (PBS, 
pH 7.4), followed by 4% paraformaldehyde in 0.2 M phosphate buffer (pH 7.4). 
Trigeminal and Dorsal Root Ganglion (lumbar 4 and 5) were rapidly dissected, 
postfixed for 2 hours and subsequently stored overnight in 20% sucrose 
(cryoprotection).  The tissue sections were blocked in OCT mounting media (Tissue-
Tek), snap-frozen in liquid nitrogen and stored at -80°C until required.  Tissue 
sections, 8µm, were cut on a Leica cryostat (CM1100), serially thaw-mounted onto 
SuperFrost Plus slides (VWR) and stored in 30% sucrose at -20°C until use. 
It should be noted that the tissue sections used in this study were provided, pre-
mounted, following this procedure. 
Immunohistochemistry Protocol 
All stages explained were conducted at room temperature, unless otherwise stated.  
After each stage which required the removal of liquids the slides were briefly air 
dried.   
The slides were placed in a Coplin jar and washed in phosphate buffered saline 
(PBS 0.01 M, pH 7.4) on an orbital shaker (160 MOT/1 minute), for 3X10 minute 
washes.  PAP Pen (Sigma) was applied around tissue sections.  To decrease the 
occurrence of non-specific binding the tissue was incubated, in a humidity chamber, 
with 10% donkey serum (PBS, 0.2% Triton X100, 0.1% sodium azide, 500µl/slide) 
for 1 hour.  The slides were then washed; three 10 min PBS washes as before.  The 
tissue was then incubated with primary antibodies (Goat anti-Rat PAR-3 [M20], 
Santa Cruz Biotechnology, CA, USA at 1:100; S-100, gift from Peninsular Medical 





School at 1:100), diluted in 5% donkey serum (PBS, 0.2 Triton X100, 0.1% sodium 
azide) and left overnight.  PAR-3 (M20) was previously characterised by Wang et al. 
(2004).  S-100 was used to identify specific cell types expressing PAR3.  The slides 
were washed (3X10 minutes) in PBS as before and incubated with secondary 
antibodies (Donkey anti-Goat AlexaFluor-555 [red] at 10µl/ml; Donkey anti-Rabbit 
AlexaFluor-488 [green] at 1:100) diluted in 5% donkey serum (PBS, 0.2 Triton X100, 
0.1% sodium azide) for 3 hours, protected from light.  The slides were washed 3X10 
minutes in PBS as before, incubated with DAPI (100ng/ml in PBS) for 15 minutes 
and washed again (1X10 minute PBS wash as before).  2 drops of FluorSave were 
applied to cover slips and placed over the tissue sections.  After being left to dry 
overnight, protected from light, the slides were sealed with clear nail varnish and 
stored in a refrigerator at 4°C in the dark.   
The images were acquired using a Nikon Eclipse 80i epifluorescence microscope 
equipped with a Nikon DS-Qi1Mc camera using NIS-Elements Software (BR 3.2, 
Nikon).  Images were taken at X10, X20 and X40 magnification.  
Results 
PAR3 Expression in TG and DRG neurons 
PAR3 immunoreactivity (IR) was detected in both TG (Fig. 1) and DRG (Fig. 2) 
tissue sections from naïve adult rats.  Its precise expression and localisation in 
neurons however could not be determined due to its strong expression in satellite 













Figure 1: Localisation of PAR3 in the TG of naïve adult rats.  PAR3 receptors appear red (a, 
b and c) and cell nuclei appear blue (b and c).  (a) Photomicrograph of section labelled for 
PAR3 receptor (X10 magnification). (b) Photomicrograph of axons double-labelled for PAR3 
and DAPI (X40 magnification).  (c) Photomicrograph of sensory neurons double-labelled for 

















Figure 2:  Localisation of PAR3 in L4/5 DRG of naïve adult rats.  PAR3 receptors appear 
red (a, b and c) and cell nuclei appear blue (b and c).  (a) Photomicrograph of section 
labelled for PAR3 receptor (X10 magnification).  (b) Photomicrograph of axons double-
labelled for PAR3 and DAPI (X40 magnification).  (c) Photomicrograph of sensory neurons 
double-labelled for PAR3 and DAPI (X40 magnification).  Scale bar (a) = 200µm, (b and c) = 
50µm. 
PAR3 Expression in Non-Neuronal cells of the TG and DRG: Satellite Cells 
PAR3 immunoreactivity was found in satellite cells of both the TG (Fig. 1c) and DRG 
(Fig. 2c) of naïve adult rats.  Primary staining appeared to be in non-neuronal cells; 
shown in ‘ring like’ structures surrounding sensory neuron cell bodies and associated 
with satellite cell nuclei in both the TG and DRG.  A primary antibody, S-100, was 
used to identify satellite cells within the TG and DRG.  The S-100 phenotypic marker 
appears green (Fig. 3a and d), the PAR3 receptor in red (Fig. 3b and e) and 
overlapping expression in yellow (Fig. 3c and f).   Areas of strong PAR3 and S-100 
co-expression in the satellite cells of both the DRG and TG can be clearly seen in 
the photomicrographs taken (Fig 5a and c).  PAR3-immunoreactivity appears to be 
found in both the cytoplasm and the plasma membrane.  PAR3 was found to be 
























Figure 3:  Co-localisation of S-100 and PAR3 in L4/5 DRG (a, b and c) and TG (d, e and f) 
sensory neurones.  Satellite cells appear green, PAR3 receptors appear red and overlapping 
of these two markers appears yellow.  (a and d) Photomicrographs of section labelled for S-
100.  (b and e) Photomicrographs of section labelled for PAR3 receptor.  (c and f) 
Photomicrographs of section double-labelled for S-100 and PAR3 receptor.  Arrow shows 
example of co-expression.  Images taken at X20 magnification.  Scale bar = 100µm. 
 
PAR3 Expression in Non-Neuronal cells of the TG and DRG: Schwann Cells 
PAR3 immunoreactivity was found in the axonal regions of both the TG and DRG 
(Fig. 4).  Co-staining with S-100 (Fig. 4a and d), a phenotypic marker of Schwann 
cells, and PAR3 (Fig. 4b and e) showed strong evidence of overlapping expression 
(Fig. 4c and f).  This co-expression can be seen clearly in the photomicrographs of 
both the TG and DRG (Fig. 5b and d).  Axonal expression of PAR3 is specifically 
localised to Schwann cells.  PAR3-immunoreactivity appears to be in both the 






















Figure 4:  Co-localisation of S-100 and PAR3 in L4/5 DRG (a, b and c) and TG (d, e and f) 
axons.  Satellite and Schwann cells appear green, PAR3 receptors appear red and 
overlapping of these two markers appears yellow.  (a and d) Photomicrographs of section 
labelled for S-100.  (b and e) Photomicrographs of section labelled for PAR3 receptor.  (c 
and f) Photomicrographs of section double-labelled for S-100 and PAR3 receptor.  Arrow 












Figure 5:  Photomicrographs showing co-localisation of S-100 and PAR3 in L4/5 DRG (a 
and b) and TG (c and d) of sensory neurons (a and c) and axons (b and d).  PAR3 receptors 
appear red, satellite and Schwann cells appear green, overlap between these two markers 
appears yellow.  Arrows show examples of co-expression.  Images taken at X40 
magnification.  Scale bar = 50µm. 






This study used immunohistochemistry to describe the distribution and quantification 
of PAR3 in the TG and DRG of naïve adult rats.  This study found clear evidence for 
the expression of PAR3 in satellite and Schwann glial cell types of both the TG and 
DRG.  However it was not possible to accurately determine PAR3 expression in 
sensory neurons, of these regions.   
PAR3 Expression in Glial Cells 
A preliminary experiment, using immunohistochemistry, showed PAR3 expression to 
be strong in the areas directly surrounding neuron cell bodies, shown to be non-
myelinating satellite cells, and in specific regions within the axons, shown to be 
myelinating Schwann cells (Figs 1 and 2).  Both satellite cells and Schwann cells 
express S100β (Woodhoo et al. 2004) and therefore this phenotypic stain was used 
to distinguish both cell types in vitro immunohistochemical analysis.  Co-staining of 
PAR3 receptors and S-100 resulted in strong overlapping-expression in both satellite 
cells and Schwann cells of the TG and DRG of naïve adult rats (Figs 3, 4 and 5). 
Satellite Cells 
PAR3 was found to have strong co-expression with S-100 in satellite cells of both the 
TG and DRG in naïve adult rats (Figs 3 and 5).  A previous study by Zhu et al. 
(2005) found PAR4 mRNA expression was seen in non-neuronal cells, such as 
satellite cells, however made no comment regarding PAR3.  PAR2 and PAR4 
expression have been described in satellite cells of both the skeletal muscle and 
DRG of mature rats, respectively (Zhu et al. 2005; Duchesne et al. 2011).  Literature 
covering PAR3 expression in satellite cells of the TG and DRG, to the best of my 
knowledge, is not available.  This would therefore be the first study to describe the 
expression of PAR3 in satellite cells of the TG and DRG in naïve adult rats. 
Schwann Cells  
PAR3 was found to have strong co-expression with S-100 in Schwann cells of both 
the TG and DRG in naïve adult rats.  To the best of my knowledge there are no 
studies which have assessed PAR3 expression in Schwann cells.  This study would 
therefore be the first to describe the expression of PAR3 in Schwann cells of both 
the TG and DRG of naïve adult rats. 
PAR3 Expression in Sensory Neurons 
Determining the expression of PAR3 in sensory neurons of the TG and DRG, in this 
study, was not possible.  PAR3 was found to be strongly expressed in the satellite 
cells surrounding the sensory neuron cell bodies.  As this study used an 
epifluorescence microscope, only a single focal plane though the tissue sample was 
able to be viewed.  Due to the close distribution of satellite cells around the neuron 
cell bodies, neurons which appeared positive may have actually been viewed 
through an overlying positive satellite cell.  It was therefore not possible to describe 
with certainty, using this technique, whether a neuron was PAR3 positive. 
A previous study conducted by Zhu and colleagues (2005) also found the expression 
of PAR protein in neurons to be equivocal, finding PAR4 expression in glial cells 
impossible to distinguish from neuronal staining.  Zhu et al. (2005) did however find 
PAR3 mRNA expression in sensory neurons of the DRG of naïve adult rats, with 
distribution shown to be irrespective of neuron size.  These findings are inconsistent 
with a study conducted by Vellani et al. (2010) in which immunohistochemistry found 





PAR3 expression was seen predominantly in small neurons of adult mice DRG.  
Although these studies were carried out on different species, Vellani et al. (2010) 
found few qualitative or quantitative differences between PAR expression in rat and 
mice DRG.  Vellani et al. (2010) found that the PAR2 antibody used in their study 
was non-specific on Western blots, resulting in the removal of PAR2 
immunohistochemistry analysis from the paper.  The antibody used in this study may 
also have had questionable specificity, resulting potentially in non-uniform staining; 
as found on some tissue samples of this study.  An antibody specificity test, such as 
conducting the immunohistochemistry procedure with only the secondary antibody 
would have helped to determine this.  Western blotting could have also been used to 
ascertain the specificity of the antibodies being used.   
The use of multiple analytical techniques, such as in situ hybridisation, 
immunohistochemistry and methods ascertaining functional expression as used by 
Vellani et al. (2010) may have proved advantageous.  As in other studies the use of 
different microscopy techniques, such as confocal microscopy, may have also aided 
the precise assessment of PAR3 expression in sensory neurons (Vellani et al. 2010; 
Shavit et al. 2011; Sokolova et al. 2012).  This technique would have proved 
particularly useful when determining neuronal PAR3 expression.   
This study may also have benefited from an increased number of sample animals.  
This would help create a wider, more accurate assessment of PAR3 expressing cells 
and allowed for statistical analysis.  To the best of my knowledge, no studies 
assessing the expression of PAR3 have been conducted in the TG. 
Functional Implications 
Glial-Neuron Interaction 
Glial cells have been shown to actively interact with neurons, contributing to 
neuronal function, neuroarchitecture, as well as maintenance of physiological 
homeostasis; under physiological and pathophysiological conditions (Eulenburg and 
Gomeza, 2010; Gwak et al. 2011).  This glial-neuron interaction can directly affect 
neuron function and has been implicated in the development and maintenance of 
pathological pain, such as seen following peripheral nerve and spinal cord injury 
(Nesic et al. 2005; Watkins et al. 2007; Gwak and Hulsebosch, 2009). 
In recent years evidence has accrued which shows the immune system can directly 
alter neuronal function (Watkins et al. 2007).  Both satellite cells and Schwann cells 
of the DRG have been found to be immune-like glial cells, comprising the resident 
immunocompetent cells of the peripheral nervous system; providing immune 
surveillance of neurons (Moalem and Tracy, 2006; Myers et al. 2006; Watkins et al. 
2007).  Both cell types are capable of producing what are considered classical 
immune substances, such as proinflammatory cytokines and chemoattractants 
(Watkins and Maier, 2002) that can interact with both CNS and PNS neurons.   
Satellite cells 
In recent years many studies have assessed the interactive role between satellite 
cells and neurons.  Satellite cells of the DRG and TG are connected by gap junctions 
and supply neurons with nutrients as well as buffer the extracellular ion and 
neurotransmitter levels (Sakuma et al. 2001; Ren and Dubner, 2010).  Following 
nerve injury, invasion of the DRG by macrophages and T cells occurs, and 
macrophages move across the satellite cells forming perineuronal rings around large 





and medium sized neurons (Hu and McLachlan, 2002; Hu et al. 2007; Ren and 
Dubner, 2010).  Their presence increases satellite cell and neuron interaction by 
paracrine signalling, known to be a major mechanism which underlies peripheral 
sensitization in the DRG (Thalakoti et al. 2007; Miller et al. 2009; Ren and Dubner, 
2010).  Recent studies suggest, following injury, satellite cells of both the TG and 
DRG show increased gap junction coupling (Dublin and Hanani, 2007; Durham and 
Garrett, 2010).  More interestingly, in the absence of noxious stimulation, no gap 
junction coupling between either DRG neurons or neurons and satellite cells can be 
seen (Ledda et al. 2009).  Therefore following peripheral noxious stimulation, 
increased satellite cell to satellite cell and satellite cell to neuronal interaction occurs, 
enhancing primary afferent input and increased neuronal excitability (Ren and 
Dubner, 2010).   This mechanism of increased communication can also affect 
neurons and satellite cells in the surrounding area (Thalakoti et al. 2007).   
TG satellite cells also promote neuron sensitisation though autocrine/paracrine 
stimulation, creating a positive feedback loop (Capuano et al. 2009).  A major 
mediator of TG nociceptive signalling is calcitonin gene-related peptide (CGRP) 
(Corato et al. 2011).  CGRP released by neurons induces IL-1β (Interleukin-1 beta) 
production by satellite cells, which in turn activates the satellite cell COX2 
(Cyclooxygenase-2) pathway, increasing PGE2 (Prostaglandin E2) production 
(Capuano et al. 2009; Ren and Dubner, 2010).  NO (Nitric oxide) production by TG 
neurons also increases PGE2 production possibly though the activation of COX1 
(Cyclooxygenase-1) in satellite cells (Capuano et al. 2009; Ren and Dubner, 2010).  
PGE2 stimulates CGRP production in TG neurons increasing sensitisation of 
nociceptors (Miller et al. 2009; Ren and Dubner, 2010). 
Sensitisation of sensory neurons of the DRG, following injury, can also occur via the 
increased levels of pro- and anti-inflammatory cytokines and chemokines (Ren and 
Dubner, 2010).  These act upon their specific receptor on DRG neurons, to generate 
ectopic discharges and enhance primary afferent input to the dorsal horn; by 
coupling to specific transient receptor potentials and sodium channels (Ren and 
Dubner, 2010).  Reviewed by Miller et al (2009).   
Schwann cells 
Surprisingly, unlike satellite cells, few papers have been published which assess the 
interaction between Schwann cells and neuron function.  Schwann cells have 
however been implicated in the recruitment of macrophages, resulting in nociceptor 
sensitisation following injury.  TNF-α is released by Schwann cells following nerve 
injury which is known to induce matrix metalloproteinase-9 (MMP-9) (Shubayev et al. 
2006; Ren and Dubner, 2010).  MMP-9 increases macrophage migration to injury 
site via mechanisms associated with the breakdown of the blood-brain barrier 
(Shubayev et al. 2006; Ren and Dubner, 2010).  
As explained satellite and Schwann cell types have been implicated as contributors 
to neuropathic pain (Watkins et al. 2007).  An increased understanding of the glial-
neuron interaction may lead to the discovery of novel therapeutic targets for the 
treatment of neuropathic pain (Ledeboer et al. 2006; Myers et al. 2006; Ledeboer et 
al. 2007; Bernardo and Minghetti, 2008; Capuano et al. 2009; Vergnolle, 2009). 
 
 





Thrombin and PAR3 in the nervous system  
Thrombin is the primary activator of PAR1, PAR3 and PAR4.  Thrombin activated 
PARs have been shown to have multiple roles in the central (CNS) and peripheral 
nervous system (PNS) these include; nociceptive signalling interaction, neurite out- 
growth and neuronal death regulation as well as microglia activation (García et al. 
2010).  The majority of the literature, however, specifically covers PAR1 and PAR4, 
with few studies specifically assessing PAR3.  This is likely due to the order of PAR 
discovery and the general view that PAR3 acts as a cofactor for PAR4, although this 
has recently been questioned (Zhu et al. 2005; Ostrowsaka and Reiser, 2008).  
There is currently a lack of information on the effect of PAR3 on synaptic function 
and behaviour (Adams et al. 2011; Almonte and Sweatt, 2011).  The current 
understanding of thrombin and PARs in pain mechanisms are reviewed by García 
and colleagues (2010).  Both PAR1 and PAR4, of the thrombin activated PARs, have 
been implicated in having a potentiating effect on TRPV1 (Transient Receptor 
Potential Vanilloid, the noxious thermal transducer protein) activity (Vellani et al. 
2010). 
Although PARs have been implicated in many roles within the nervous system, the 
functional role of PAR3 remains generally unclear (Ostrowska and Reiser, 2008).  As 
shown glial neuron interaction can result in increased nociception following injury.  
Thrombin’s release is known to occur following cell damage, and PARs have been 
strongly implicated in the response to pain in both the CNS and PNS (García et al. 
2010).  It is therefore possible that although mechanistic links have yet to be made, 
PAR3 may play a role in these pathways; i.e. PAR3 mediated glial activation with 
subsequent neuron-glial interaction. 
Conclusion 
Of the PAR family, PAR3 remains the most elusive, with its functional role relatively 
unknown (Ostrowsaka and Reiser, 2008).   
To the best of my knowledge, there are no studies which specifically assess the 
potential role of PAR3, or any PARs, in interactions between neurons and glial cells.  
The unequivocal evidence of interaction between these two cell types, as well as the 
knowledge PAR3 is activated by thrombin; a serine protease released following 
injury, suggests that there is the possibility of an interactive role of PAR3 expressing 
glial cells with neurons of the DRG and TG.  Depending on PAR3 expression within 
neurons, this receptor may also play a major role in other mechanisms within the 
nervous system; such as nociception, inflammation and neurodegeneration. 
In summary this study found PAR3 to be strongly expressed in non-neuronal glial 
cells (satellite cells and Schwann cells) of the TG and DRG of naïve adult rats.  
However the expression of PAR3 in sensory neurons of both the TG and DRG 
proved inconclusive. 
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